Introduction: Psoriatic arthritis (PsA) is a spondyloarthritis that occurs in up to 30% of psoriasis patients. Patients with PsA are at risk for decreased quality of life due to both joint and skin symptoms, impaired physical function
Improvements in this and other clinical and patient-reported end points, including swollen and tender joint counts, Psoriasis Area and Severity Index score, physical function, and quality of life, were maintained, extending over 52 weeks of treatment among patients initially randomized to apremilast. Apremilast's safety profile has been acceptable, with diarrhea and nausea being the most common adverse events, with no evidence for an increased risk of infection or need for laboratory monitoring.
The PALACE pivotal data indicate that apremilast presents a new option for the treatment of PsA that may be appropriate for Electronic supplementary material The online version of this article (doi:10.1007/s40744-014-0005-4) contains supplementary material, which is available to authorized users.
INTRODUCTION
Psoriatic arthritis (PsA) is an inflammatory spondyloarthritis associated with psoriasis. Estimates of PsA prevalence among patients with psoriasis vary widely (6.6-48.0%) [1, 2] . In one study that included rheumatologist assessment, PsA was found in 30% of a sample of patients with psoriasis [3] . Many individuals with PsA are undiagnosed [3] [4] [5] . In the Prevalence of Psoriatic Arthritis in Adults with Psoriasis: An Estimate from Dermatology Practice (PREPARE) study, 41% of the detected PsA cases had not been diagnosed before study entry [3] .
PsA is a multi-domain disease, affecting the musculoskeletal axis, skin, and nails [6] [7] [8] .
Symptoms of PsA may include joint pain and swelling, enthesitis, dactylitis and, in those patients with active skin involvement, itching, all of which may lead to impaired physical function, work limitations, emotional distress and social embarrassment. These disease manifestations impact patients' health-related quality of life (HRQOL) to a similar extent as other arthropathies and chronic diseases such as diabetes or heart disease [9] [10] [11] . To achieve a more timely diagnosis of PsA, primary care physicians and dermatologists may benefit from education and simple questionnaires that help identify signs of inflammatory arthritides, flag signs and symptoms of PsA such as enthesitis and dactylitis, and identify immunemodulated joint inflammation [12] .
Currently, a range of systemic therapies are available for the treatment of PsA, including conventional oral therapies and biologic agents.
Long-term use of these agents may be limited by safety and tolerability issues, variable efficacy, route of administration (injection/infusion with biologic agents) and cost [13] [14] [15] . Methotrexate is among the most widely used conventional oral therapies [16] . However, evidence of the effectiveness of methotrexate for treatment of PsA is limited and conflicting [17] [18] [19] [20] [21] , and methotrexate has been associated with risks of hepatic, pulmonary and bone marrow toxicity [16] . Biologic agents that act as tumor necrosis factor (TNF) inhibitors-etanercept, adalimumab, infliximab, golimumab and certolizumab-have demonstrated efficacy in improving the signs and symptoms of PsA in large, well-controlled clinical studies [12, 14, 22] , but patients sometimes experience waning efficacy over time [13] or rare but serious adverse events (AEs), such as infection and non-melanoma skin cancer [14] . Other factors that limit the use of biologic agents include injection-related anxiety and cost [15] . [23] . This review will focus on the efficacy and safety of apremilast in the treatment of PsA.
Rheumatologists
The only known mode of action of apremilast is selective PDE4 inhibition [24] , mediated via PDE4 binding at apremilast's dialkoxyphenyl pharmacophore, a feature shared with other PDE4 inhibitors [24] . PDE enzymatic activity is the sole means of cyclic adenosine monophosphate (cAMP) degradation to AMP in cells [25] . cAMP is an intracellular secondary messenger responsible for a wide array of cellular functions, including regulation of inflammatory signaling and immune homeostasis [24] . PDE4 comprises a group of isoforms among many in the PDE enzyme family. In vitro studies demonstrate that apremilast selectively inhibits activity of several PDE4 isoforms, including the long (4B1, 4C1), short (4B2, 4D2) and super-short (4A1A) isoforms, with no significant inhibition of other PDEs, cell surface receptors or kinases ( Fig. 1 ) [24] .
Fig. 1
Effect of apremilast on phosphodiesterase (PDE) enzymatic activity. Enzymatic reactions were carried out in 100 nM cyclic adenosine monophosphate as a substrate, except for PDE5A1 and PDE9A2 (100 nM cyclic guanosine monophosphate) and retinal rod PDE6 (100 lM). Data are shown as the mean and standard deviation (SD) from assays performed in duplicate. Reproduced with permission from Schafer et al. [24] Each PDE4 isoform is found, in relatively varying degrees, in immune cells such as monocytes, T cells and neutrophils [25] . In human peripheral blood mononuclear cells, apremilast-mediated PDE4 inhibition, in response to prostaglandin E 2 , results in elevated intracellular cAMP concentrations [24] . In turn, the apremilast-mediated rise in cAMP concentrations causes downstream changes in gene expression via induction of cAMP response element-binding/activating transcription factor 1 phosphorylation and binding to the cAMP response element DNA sequence, thus driving cAMP response elementdependent gene expression and inhibition of nuclear factor-jB transcriptional activity ( Fig. 2 ) [24] .
Specific changes in protein production observed in human peripheral blood monocytes with apremilast include inhibition of lipopolysaccharide-stimulated production of TNF-a and cytosine phosphodiester-guanine (CpG) oligonucleotide-stimulated production of interferon-a [24] . Apremilast did not production, other in vitro experiments show that apremilast has no effect on T-cell or B-cell clonal expansion or on antibody responses in vivo using the antigen-specific mouse B-cell transfer model [24] , suggesting that key aspects of adaptive immune system responses may be relatively unaffected by apremilast treatment.
In the psoriasis and arthritis in vivo models, apremilast administration leads to reductions in In PALACE 1, a total of 504 patients were randomized and received one or more doses of placebo, apremilast 20 mg twice daily (BID), or apremilast 30 mg BID, comprising the intent-totreat (ITT) population [30] . As shown in Fig. 4 , patients whose swollen and tender joint counts had not improved by C20% at Week 16 were considered non-responders and were required to be re-randomized (1:1) to apremilast 20 mg BID or 30 mg BID if they were initially randomized to placebo, or continued on their Week 16 (intent to treat, LOCF) Fig. 4) [37] will provide valuable information about the long-term efficacy and safety of apremilast treatment.
APREMILAST SAFETY IN PHASE III CLINICAL TRIALS
Apremilast has demonstrated an acceptable long-term safety and tolerability profile in the PALACE 1, 2, and 3 pivotal trials. In a pooled analysis of safety from patients in these three trials [39], a total of 1,493 patients received study medication and were included in the safety population (placebo: n = 495; apremilast 20 mg BID: n = 501; apremilast 30 mg BID: n = 497). The most common adverse events Diarrhea and nausea, the most common gastrointestinal AEs, occurred most often in the first 2 weeks of exposure to apremilast, with a reduced incidence of these AEs after the first month of dosing [39] . Nausea and diarrhea were predominantly mild or moderate in severity in the weeks 0 to C24 apremilast-exposure period [40] .
During the weeks 0 to C52 apremilast-exposure period, no new severe AEs of diarrhea, nausea, URTI, or nasopharyngitis were reported after the weeks 0 to C24 apremilast-exposure period [39] .
Serious AEs occurred at low rates, were comparable across treatment groups (Table 4) and did not increase with long-term apremilast exposure based on the exposure-adjusted 
PRACTICAL POINTS: APREMILAST'S PLACE IN THERAPY
Currently available algorithms for PsA treatment guide clinicians through treatment choices, beginning with non-steroidal antiinflammatory drugs, followed by conventional Placebo-controlled phase (weeks 0 to 24) a Apremilast-exposure period (weeks 0 to ‡ 
